Suppr超能文献

可发酵碳水化合物(FODMAPs)加重炎症性肠病患者的功能性胃肠症状:一项随机、双盲、安慰剂对照、交叉、再挑战试验。

Fermentable Carbohydrates [FODMAPs] Exacerbate Functional Gastrointestinal Symptoms in Patients With Inflammatory Bowel Disease: A Randomised, Double-blind, Placebo-controlled, Cross-over, Re-challenge Trial.

机构信息

King's College London, Diabetes and Nutritional Sciences Division, UK.

King's College Hospital NHS Foundation Trust, Department of Nutrition and Dietetics, UK.

出版信息

J Crohns Colitis. 2017 Dec 4;11(12):1420-1429. doi: 10.1093/ecco-jcc/jjx073.

Abstract

BACKGROUND AND AIMS

Preliminary evidence suggests that fermentable carbohydrate restriction might ameliorate functional gastrointestinal symptoms [FGS] in inflammatory bowel disease [IBD]. Our aim was to determine whether fermentable carbohydrates exacerbate FGS in IBD using a randomised, double-blinded, placebo-controlled, re-challenge trial.

METHODS

Patients with quiescent IBD and FGS responsive to a low FODMAP diet were allocated to a series of 3-day [d] fermentable carbohydrate challenges in random order [fructan, 12 g/d; galacto-oligosaccharides [GOS] 6 g/d; sorbitol, 6 g/d; and glucose placebo, 12 g/d], each separated by a washout period. Symptoms and stool output were measured daily during the challenges.

RESULTS

Thirty-two patients with IBD, fulfilling criteria for irritable bowel syndrome, functional bloating, or functional diarrhoea, were recruited and data were available for 29 patients completing all arms [12 Crohn's disease, 17 ulcerative colitis]. Significantly fewer patients reported adequate relief of FGS on the final day day of the fructan challenge [18/29, 62.1%] compared with glucose [26/29, 89.7%] [p = 0.033]. There was greater severity of pain [1.1 vs 0.5, p = 0.004], bloating [1.3 vs 0.6, p = 0.002], flatulence [1.5 vs 0.7, p = 0.004], and faecal urgency [0.9 vs 0.4, p = 0.014] on the final day of fructan challenge compared with glucose.

CONCLUSIONS

At the relatively high doses used, fructans, but not GOS or sorbitol, exacerbated FGS in quiescent IBD. Further research is required to determine whether a low FODMAP diet reduces FGS in IBD and the degree of FODMAP restriction required for symptom improvement.

摘要

背景和目的

初步证据表明,可发酵碳水化合物限制可能改善炎症性肠病[IBD]中的功能性胃肠症状[FGS]。我们的目的是通过一项随机、双盲、安慰剂对照、再挑战试验来确定可发酵碳水化合物是否会加重 IBD 中的 FGS。

方法

患有静止性 IBD 和对低 FODMAP 饮食有反应的 FGS 的患者被随机分配到一系列 3 天[天]的可发酵碳水化合物挑战中[果糖,12 克/天;半乳糖寡糖[GOS]6 克/天;山梨糖醇,6 克/天;和葡萄糖安慰剂,12 克/天],每个挑战之间都有洗脱期。在挑战期间,每天测量症状和粪便排出量。

结果

招募了 32 名符合肠易激综合征、功能性腹胀或功能性腹泻标准的 IBD 患者,其中 29 名患者完成了所有试验[12 名克罗恩病,17 名溃疡性结肠炎]的数据可用。在果糖挑战的最后一天,报告 FGS 得到充分缓解的患者明显少于葡萄糖[26/29,89.7%] [p = 0.033]。疼痛[1.1 对 0.5,p = 0.004]、腹胀[1.3 对 0.6,p = 0.002]、气胀[1.5 对 0.7,p = 0.004]和粪便急迫感[0.9 对 0.4,p = 0.014]的严重程度显著更高果糖挑战的最后一天与葡萄糖相比。

结论

在使用的相对较高剂量下,果糖会加重静止性 IBD 中的 FGS,但 GOS 或山梨糖醇不会。需要进一步研究以确定低 FODMAP 饮食是否可以减少 IBD 中的 FGS 以及改善症状所需的 FODMAP 限制程度。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验